Clinical Analysis Of The Symptoms Of Parkinson’s Disease Patients With Glucose-lipid Metabolism Disorder

BackgroundParkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease. At present, China has more than 2 million PD patients, accounting for about half of the total number of patients in the world, the prevalence of PD in the population over age 65 is about 1.7%. Parkinson’s disease with strong disability comes out serious harm to human health and quality of life, to the patient himself, family and community has brought a heavy burden. The long-term hyperglycemia in diabetes has been clearly defined as a chronic damage to the nervous system, leading to neurological disorders. The correlation between diabetes and neurodegenerative diseases is one of the latest hot spots. Recently, the incidence rates of Parkinson’s disease and diabetes mellitus have been going up on a global scale, which leads to a larger number of patients with Parkinson’s disease and diabetes. It had been reported both at home and abroad that diabetes is a risk factor for Parkinson’s disease, and symptoms might be more serious. However, more research needs to be done to confirm this opinion. Normal brain substantia nigra are particularly vulnerable to oxidative stress, ROS can promote the oxidation of neural membrane systems and destroy the function of dopaminergic neurons. Different independent research teams drew different conclusions about the association between serum lipid level and Parkinson’s disease, which is still a controversy.ObjectiveTo investigate the effect of diabetes mellitus and serum lipid level on Parkinson’s disease, analyze and summarize the clinical characteristics and therapeutic strategies of Parkinson’s disease patients.MethodsPatients hospitalized in 2nd Hospital of School of medicine, Zhejiang University during 2014-2015 are divided into groups complicated with diabetes. We assessed PD patients using Hoehn Yahr classification and evaluated diabetic group and the control group with motor symptoms and dementia.120 PD patients, who haven’t taken lipid-lowering drugs recently were selected, and 120 patients without neurological disorders, whose age, sex and nationality matched the PD patients chosen as control group. The levels of blood lipids were examined, and compared them between the two groups.SPSS21.0 was used to compare sex, age, age of onset, duration, initial symptoms, smoking, alcohol drinking and combined diseases by ANOVA test, t-test, crosstab. P<0.05 stands for the statistical significance.Results1.The age, age of onset, duration of all the patients, the onset age of the patients showed normal curve, and duration showed positive skewness distribution.2.Education level and life style and no significant differences among all the patients, mainly in the education, smoking history, drinking history and other disease history.3. The average H-Y staging is 3.16±0.86 in the diabetes group, while that is 2.89±0.94 in the control group with no significance.4. In the diabetes group, patients displayed greater postural instability and gait difficulty. There were no differences in bradykinesia, rigidity, or tremor between cases and controls.5.Our study suggested that PD patients with diabetes are more likely to have dementia.6. Compared with the control group, the serum total cholesterol, triglyceride, high and low density lipoprotein cholesterol levels in PD patients had no significant differences (P>0.05).7. There were also no significant difference levels of serum lipids and lipoproteins among different severity PD patients.ConclusionsThe average H-Y staging is 3.16±0.86 in the diabetes group, while that is 2.89±0.94 in the control group with no significance. In the diabetes group, patients displayed greater postural instability and gait difficulty. There were no differences in bradykinesia, rigidity, or tremor between cases and controls. Our study suggested that PD patients with diabetes are more likely to have dementia. Compared with the control group, the serum total cholesterol, triglyceride, high and low density lipoprotein cholesterol levels in PD patients had no significant differences. There were also no significant difference levels of serum lipids and lipoproteins among different severity PD patients.